Skip to main content
Equibles

Christine Pellizzari

Board Member

Imunon, Inc. (IMNN)

Board Member

Tempest Therapeutics, Inc. (TPST)

Equibles does not estimate personal net worth.

Get an email with a short summary when Imunon, Inc. publishes a filing, an earnings call transcript or a press release.

Get IMNN alerts

About Christine Pellizzari

Christine Pellizzari is recorded as Board Member at Imunon, Inc. (IMNN) and Board Member at Tempest Therapeutics, Inc. (TPST) since June 16, 2023. The newest filing on record that lists Christine Pellizzari as Board Member at Imunon, Inc. (IMNN) is dated May 4, 2026. Tempest Therapeutics, Inc. reported in an 8-K filed May 22, 2026 that Christine Pellizzari resigned as Board of Directors, effective May 22, 2026. Tempest Therapeutics, Inc. reported in an 8-K filed June 16, 2023 that Christine Pellizzari was appointed Class II director. The proxy statement of INSMED Inc reports total compensation of $3,232,896 for Christine Pellizzari in fiscal 2020, including a base salary of $476,150. Disclosed compensation is on record for 4 fiscal years. Imunon, Inc. is classified in the Biotechnology industry within the Healthcare sector. Tempest Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Imunon, Inc. includes Corinne Le Goff (CEO and Board Member), Michael Tardugno (CEO and Chairman), Stacy Lindborg (CEO and Board Member) and 7 others.

“On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.”
Tempest Therapeutics, Inc. Form 8-K, filed May 22, 2026 · Read the filing
“The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Tempest Therapeutics, Inc. Form 8-K, filed June 16, 2023 · Read the filing

Affiliation history

Company network

Imunon, Inc.

IMNN

Current role

Biotechnology · Healthcare

Board Member

Leadership on record at Imunon, Inc.

Leadership on record at Tempest Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 INSMED Inc (INSM) $476,150 $3,232,896
2019 INSMED Inc (INSM) $449,200 $2,709,564
2018 INSMED Inc (INSM) $436,110 $2,030,589
2017 INSMED Inc (INSM) $415,340 $1,977,865

Recent activity